Do You Gain Weight Back After Stopping GLP-1 Drugs?

Across the published evidence, the pattern is consistent: stopping a GLP-1 medication is typically followed by meaningful weight regain. The clearest figure comes from an extension analysis of the STEP 1 trial of semaglutide 2.4 mg. After the on-treatment phase ended, participants who came off the drug and its lifestyle support regained about two-thirds of the weight they had lost over roughly the following year, and the improvements seen in blood pressure, lipids, and other cardiometabolic markers largely returned toward baseline (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

Read that as a study finding describing a group average, not a forecast for one person. Individual trajectories vary, and some people hold more of their loss than others. But the direction is not ambiguous across trials, and it is consistent with how the drugs are labeled — as long-term adjuncts to diet and exercise, not a short course.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) reduce appetite and slow gastric emptying, which lowers calorie intake while the drug is in the system. That mechanism is the point — and it's also why the effect fades when the drug leaves.

Two things happen on stopping. First, the appetite-suppressing signal goes away, so hunger and food reward typically return toward pre-treatment levels. Second, the body resists weight loss through well-documented adaptations: levels of hunger-related hormones rise, satiety signals fall, and resting energy expenditure can drop relative to the new lower weight. This "defense of body weight" is the same biology that makes weight regain common after any successful weight loss — the medication was counteracting it, and removing the medication removes that counterweight.

The practical takeaway: regain after stopping is an expected physiological response, not evidence that someone "did it wrong." Framing it that way is both more accurate and more useful when planning what comes next.

Two randomized withdrawal trials isolate the effect of staying on the drug. In STEP 4 (Rubino et al., JAMA, 2021), everyone took semaglutide for a 20-week run-in, then was randomized to continue or switch to placebo. Over the following 48 weeks, the continuation group lost roughly 7.9% more body weight on average, while the placebo group regained about 6.9% — a swing that comes almost entirely from whether treatment continued.

SURMOUNT-4 (Aronne et al., JAMA, 2024) ran the same design with tirzepatide after a 36-week lead-in. Again, those who continued kept losing weight, while those switched to placebo regained a substantial portion of what they'd lost. Different drug, same lesson: for many patients, the benefit is sustained by ongoing treatment rather than "banked" after a fixed period.

Because continuation is what preserves results in the trials, the most evidence-supported strategy for holding weight is staying on the medication — sometimes called a maintenance dose. In practice this can mean remaining at the dose that achieved the loss, or, for some patients, a clinician-guided lower dose intended to maintain rather than drive further loss. Maintenance dosing for weight management should be individualized by a licensed prescriber; there is no one-size-fits-all maintenance dose, and the right approach depends on response, side effects, cost, and goals.

It's worth being precise about what the evidence does and doesn't say. The trials show continuation preserves loss better than stopping. They do not establish that a reduced maintenance dose works as well as the full dose for everyone, and long-term maintenance-dose data are still maturing. This is exactly the kind of nuance to work through with a clinician rather than self-managing.

No lifestyle program has been shown in trials to fully prevent regain after stopping a GLP-1 drug. But the broader obesity and weight-maintenance literature consistently associates several behaviors with better maintenance of any weight loss, and clinicians commonly emphasize them when a taper or stop is on the table:

• Protein-forward eating and resistance training to help preserve lean mass, since muscle loss can accompany rapid weight loss and lower resting energy needs.
• Regular physical activity, which is more strongly linked to maintaining weight loss than to producing it.
• Structured self-monitoring (food, weight, or activity), repeatedly associated with better long-term maintenance in weight-loss registries.
• Sleep and stress management, given their effects on appetite-regulating hormones.

These are supportive measures, not a substitute for the medication's effect. Presenting them as a guaranteed replacement for continued treatment would overstate the evidence.

If you and a clinician decide to come off a GLP-1 medication — whether for cost, side effects, pregnancy planning, having reached a goal, or any other reason — an exit is something to plan rather than to do abruptly. A typical provider conversation covers:

• Why now, and the alternatives — including whether a maintenance dose is appropriate before stopping entirely.
• Taper vs. stop — some clinicians step the dose down rather than discontinuing in one move; the evidence base for tapering is thinner than for continuation, so this is a clinical judgment call.
• A monitoring plan — how weight, blood pressure, glucose, and lipids will be tracked after stopping, since the trials show these can move back toward baseline.
• A re-start pathway — what would prompt resuming treatment, so regain isn't met with silence.
• Lifestyle scaffolding put in place before the last dose, not after.

Telehealth platforms such as ShedRx, Ivim Health, Henry Meds, Eden, MEDVi, and others connect patients with licensed clinicians who can manage starts, maintenance, tapers, and stops; manufacturer channels like NovoCare and LillyDirect support access to branded products. Compounded GLP-1 formulations offered by some providers are not FDA-approved, and pricing and availability vary widely — always verify current pricing at the source and confirm any plan with your own prescriber.

This article is for adults 18 and older and is educational, not medical advice. It does not diagnose, treat, cure, or prevent any condition. Efficacy and regain figures cited here are findings from published trials or FDA labeling, attributed as such, and describe study populations rather than predicting your result. GLP-1 medications are prescription-only and require a consultation with a licensed clinician; do not attempt to obtain prescription medication without a prescription, and avoid grey-market or research-chemical sources. Compounded medications are not FDA-approved. GLP1 Samples is an independent reviews site — it does not sell, ship, or prescribe medication, and placement is never for sale. Any prices referenced are provider-attributed and change frequently; verify current pricing and availability at the source.